Abstract
Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.
Original language | English |
---|---|
Pages (from-to) | 302-306 |
Number of pages | 5 |
Journal | Journal of the Peripheral Nervous System |
Volume | 15 |
Issue number | 4 |
DOIs | |
Publication status | Published - Dec 2010 |
Keywords
- antibodies
- ganglioside complexes
- GQ1b
- IgM
- MAG
- monoclonal gammopathy
- neuropathy
- rituximab
- sulfatide
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)